Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Other Operating Expenses (2022 - 2025)

Lyra Therapeutics (LYRA) has disclosed Other Operating Expenses for 4 consecutive years, with $11.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $11.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4000.0, a 100.02% decrease, with the full-year FY2024 number at $24.7 million, up 1452.45% from a year prior.
  • Other Operating Expenses was $11.8 million for Q3 2025 at Lyra Therapeutics, up from -$11.8 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $24.7 million in Q2 2024 to a low of -$11.8 million in Q2 2025.
  • A 4-year average of $4.6 million and a median of $1.5 million in 2022 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: surged 1452.7% in 2024, then tumbled 147.74% in 2025.
  • Lyra Therapeutics' Other Operating Expenses stood at $1.3 million in 2022, then grew by 20.97% to $1.6 million in 2023, then plummeted by 100.25% to -$4000.0 in 2024, then soared by 295150.0% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Other Operating Expenses are $11.8 million (Q3 2025), -$11.8 million (Q2 2025), and -$4000.0 (Q4 2024).